Adi Diab

University of Jordan — JO

Medicine · Health Sciences

60h-index22.4kcitations462works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(299), CAR-T cell therapy research(154), Immunotherapy and Immune Responses(142), Melanoma and MAPK Pathways(59), Colorectal Cancer Treatments and Studies(46)

Publications462 total

Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature
Melanoma Research·2025
Editor’s Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Cancer Discovery·2025Open Access
Obesity is associated with higher 90-day and 2-year complication rates following surgical fixation of upper extremity fractures: A nationwide analysis
Injury·2025· 1 cited
590 A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME-encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma
Regular and Young Investigator Award Abstracts·2025Open Access
Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence
Kidney International Reports·2025Open Access
Prevalence and socioeconomic patterns of leishmaniasis in Libya: a retrospective analysis of health center data
African Geographical Review·2025
2902P Health care providers (HCP) perception and patient (pts) self-declared digital literacy (DL) and clinical impact on remote pts monitoring (RPM) and symptom burden in 4,753 patients across 110 centers in France and Belgium
Annals of Oncology·2025
Hypothyroidism increases risk of early medical and late mechanical complications after primary total knee arthroplasty: A propensity-matched cohort study
Journal of Orthopaedics·2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
OncoImmunology·2025· 1 citedOpen Access
Association between Perceived Social Support and Recovery among Patients with Psychiatric Disorders
Tanta Scientific Nursing Journal·2025Open Access
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma
Journal of Clinical Oncology·2025· 7 citedOpen Access
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Journal of Clinical Oncology·2025· 1 cited
Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB).
Journal of Clinical Oncology·2025· 5 cited
Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
Journal of Clinical Oncology·2025
SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.
Journal of Clinical Oncology·2025
OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma.
Journal of Clinical Oncology·2025
Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY).
Journal of Clinical Oncology·2025
Interrogating the interleukin-6 (IL-6)/IL-23/T-helper (Th)17 axis in immunotherapy toxicity: Mechanistic insights and therapeutic implications.
Journal of Clinical Oncology·2025· 2 cited
A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.
Journal of Clinical Oncology·2025· 1 cited
Abstract CT245: Neoadjuvant immune checkpoint blockade + a prebiotic food-enriched dietary intervention to optimize immune response in melanoma: NEO-PreFED
Cancer Research·2025
page 1 of 24Next →

Frequent Co-authors

Sapna P. Patel(17), Michael A. Davies(17), Michael T. Tetzlaff(15), Isabella C. Glitza(14), Rodabe N. Amaria(14), Padmanee Sharma(14), James P. Allison(14), Patrick Hwu(13), Jennifer A. Wargo(13), Scott E. Woodman(12), Jeffrey E. Gershenwald(12), Alexander J. Lazar(11), Hussein A. Tawbi(11), Víctor G. Prieto(9), Noha Abdel‐Wahab(9), Vancheswaran Gopalakrishnan(8), Wen-Jen Hwu(8), María E. Suarez‐Almazor(8), Patrick Hwu(8), Daniel H. Johnson(8)